Search

Your search keyword '"Leppa, Sirpa"' showing total 259 results
Start Over Author "Leppa, Sirpa"
259 results on '"Leppa, Sirpa"'

1. Enteropathy-associated T cell lymphoma subtypes are characterized by loss of function of SETD2

Author

Moffitt, Andrea B, Ondrejka, Sarah L, McKinney, Matthew, Rempel, Rachel E, Goodlad, John R, Teh, Chun Huat, Leppa, Sirpa, Mannisto, Susanna, Kovanen, Panu E, Tse, Eric, Au-Yeung, Rex KH, Kwong, Yok-Lam, Srivastava, Gopesh, Iqbal, Javeed, Yu, Jiayu, Naresh, Kikkeri, Villa, Diego, Gascoyne, Randy D, Said, Jonathan, Czader, Magdalena B, Chadburn, Amy, Richards, Kristy L, Rajagopalan, Deepthi, Davis, Nicholas S, Smith, Eileen C, Palus, Brooke C, Tzeng, Tiffany J, Healy, Jane A, Lugar, Patricia L, Datta, Jyotishka, Love, Cassandra, Levy, Shawn, Dunson, David B, Zhuang, Yuan, Hsi, Eric D, and Dave, Sandeep S

Subjects
Genetics, Cancer, Hematology, Lymphoma, Rare Diseases, Clinical Research, Biotechnology, Digestive Diseases, 2.1 Biological and endogenous factors, Aetiology, Animals, DNA Copy Number Variations, Enteropathy-Associated T-Cell Lymphoma, Female, Gene Expression Profiling, Gene Silencing, Histone-Lysine N-Methyltransferase, Humans, Male, Mice, Knockout, Middle Aged, Mutation, Sequence Analysis, DNA, T-Lymphocytes, Medical and Health Sciences, Immunology
Abstract

Enteropathy-associated T cell lymphoma (EATL) is a lethal, and the most common, neoplastic complication of celiac disease. Here, we defined the genetic landscape of EATL through whole-exome sequencing of 69 EATL tumors. SETD2 was the most frequently silenced gene in EATL (32% of cases). The JAK-STAT pathway was the most frequently mutated pathway, with frequent mutations in STAT5B as well as JAK1, JAK3, STAT3, and SOCS1 We also identified mutations in KRAS, TP53, and TERT Type I EATL and type II EATL (monomorphic epitheliotropic intestinal T cell lymphoma) had highly overlapping genetic alterations indicating shared mechanisms underlying their pathogenesis. We modeled the effects of SETD2 loss in vivo by developing a T cell-specific knockout mouse. These mice manifested an expansion of γδ T cells, indicating novel roles for SETD2 in T cell development and lymphomagenesis. Our data render the most comprehensive genetic portrait yet of this uncommon but lethal disease and may inform future classification schemes.

Published
2017

2. Disruption of KLHL6 Fuels Oncogenic Antigen Receptor Signaling in B-cell Lymphoma

Author

Meriranta, Leo, primary, Sorri, Selma, additional, Huse, Kanutte, additional, Liu, Xiaonan, additional, Spasevska, Ivana, additional, Zafar, Sadia, additional, Chowdhury, Iftekhar, additional, Dufva, Olli, additional, Sahlberg, Eerika, additional, Tandaric, Luka, additional, Karjalainen-Lindsberg, Marja-Liisa, additional, Hyytiainen, Marko, additional, Varjosalo, Markku, additional, Myklebust, June H., additional, and Leppa, Sirpa, additional

Published
2024
Full Text
View/download PDF

3. MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma : the Nordic Lymphoma Group MCL7 VALERIA trial

Author

Jerkeman, Mats, Kolstad, Arne, Hutchings, Martin, Pasanen, Annika, Meriranta, Leo, Niemann, Carsten Utoft, Jorgensen, Rasmus Rask Kragh, El-Galaly, Tarec Christoffer, Riise, Jon, Leppa, Sirpa, Christensen, Jacob Haaber, Sonnevi, Kristina, Pedersen, Lone Bredo, Wader, Karin Fahl, Glimelius, Ingrid, Jerkeman, Mats, Kolstad, Arne, Hutchings, Martin, Pasanen, Annika, Meriranta, Leo, Niemann, Carsten Utoft, Jorgensen, Rasmus Rask Kragh, El-Galaly, Tarec Christoffer, Riise, Jon, Leppa, Sirpa, Christensen, Jacob Haaber, Sonnevi, Kristina, Pedersen, Lone Bredo, Wader, Karin Fahl, and Glimelius, Ingrid

Abstract

Despite improvements in treatment of mantle cell lymphoma (MCL), most patients eventually relapse. In this multicenter phase 1b/2 trial, we evaluated safety and efficacy of minimal residual disease (MRD)-driven venetoclax, lenalidomide, and rituximab (venetoclax-R2) in relapsed/refractory (R/R) MCL and explored the feasibility of stopping treatment in molecular remission. The primary end point was overall response rate (ORR) at 6 months. After dose escalation, the recommended phase 2 dose was lenalidomide 20 mg daily, days 1 to 21; venetoclax 600 mg daily after ramp-up; and rituximab 375 mg/m(2) weekly for 4 weeks, then every 8 weeks. MRD monitoring by RQ-PCR was performed every 3 months. When MRD-negativity in the blood was reached, treatment was continued for another 3 months; if MRD-negativity was then confirmed, treatment was stopped. In total, 59 patients were enrolled, with a median age of 73 years. At 6 months, the ORR was 63% (29 complete remission [CR], 8 partial remission [PR]), and 40% (4 CR, 2 PR) for patients previously failing a Bruton tyrosine kinase (BTK) inhibitor. Median progression-free survival (PFS) was 21 months, with median overall survival of 31 months. TP53 mutation was associated with inferior PFS (P < .01). Overall, 28 patients (48%) discontinued treatment in molecular remission, and 25 remain MRD negative after a median of 17.4 months. Hematological toxicity was frequent, with 52 of 59 (88%) patients with G3-4 neutropenia and 21 of 59 (36%) patients with G3-4 thrombocytopenia. To conclude, MRD-driven venetoclax-R2 is feasible and tolerable and shows efficacy in R/R MCL, also after BTK inhibitor failure.

Published
2024
Full Text
View/download PDF

4. Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial

Author

Hertzberg, Mark, Grigg, Andrew, Cannell, Paul, Quach, Hang, Opat, Stephen, Tam, Constantine, Marlton, Paula, Janssens, Ann, Offner, Fritz, Van eygen, Koen, Sangha, Randeep, Mckay, Pam, Wilson, Jonathan, Van Der Jagt, Richard, Roitman, Daryl, Trneny, Marek, Mayer, Jiri, Le Du, Katell, Solal-Celigny, Philippe, Cartron, Guillaume, Foussard, Charles, Frickhofen, Norbert, Schmidt, Peter, Graeven, Ullrich, Gaska, Tobias, Schlag, Rudolf, Sökler, Martin, Prange-Krex, Gabriele, Florschütz, Axel, Lindemann, Hans-Walter, Schimmelpfennig, Christoph, Tonndorf, Solveig, Hänel, Mathias, Hess, Georg, Schalk, Enrico, Hütten, Heiko, Doelken, Gottfried, Pfreundschuh, Michael, Keller, Ulrich, Herold, Michael, Forstpointner, Roswitha, Vehling-Kaiser, Ursula, Hoffmann, Martin, Borbenyi, Zita, Udvardy, Miklos, Demeter, Judit, Rambaldi, Alessandro, Morra, Enrica, Massimo, Federico, Majolino, Ignazio, Balzarotti, Monica, Semenzato, Gianpietro, Canales Albendea, Miguel Angel, Peñalver Parraga, Francisco Javier, Soler Campos, Alfonso, Sancho Cia, Juan Manuel, Marquez Navarro, Jose Antonio, Grande Garcia, Carlos, Nilsson-Ehle, Herman, Mccarthy, Helen, Pocock, Chris, Sadullah, Shalal, Malladi, Ram, Radford, John, Kanfer, Ed, Kruger, Anton, Culligan, Dominic, Dyer, Martin, Pettengell, Ruth, Seymour, John, Gribben, John, Al-Ismail, Saad, Al-Refaie, Faris, Blesing, Norbert, Macnamara, Christopher, O'callaghan, Ann, Haynes, Andrew, Follows, George, Johnson, Roderick, Cunningham, David, Bowles, Kristian, Collins, Graham, Gallop-Evans, Eve, Robinson, Stephen, Subash, Chezhian, Bailey, James, Holden, Viran, Neidhart, Jeffrey, De Oliveira, Moacyr, Tezcan, Haluk, Kim, Kevin, Kambhampati, Suman, Lanier, Keith, Mcclean, John, Tobinai, Kensei, Hatake, Kiyohiko, Ogura, Michinori, Uchida, Toshiki, Ando, Kiyoshi, Kinoshita, Tomohiro, Höhler, Thomas, Stauder, Heribert, Kirsch, Andreas, Koenigsmann, Michael, Kremers, Stephan, Illmer, Thomas, Witzens-Harig, Mathias, La Roseé, Paul, Dürig, Jan, Kneba, Michael, Hensel, Manfred, Fuxius, Stefan, Bergmann, Lothar, Hübel, Kai, Buske, Christian, Marks, Reinhard, Wulf, Gerald, Lerchenmueller, Christian, Schmits, Rudolf, Reinwald, Mark, Lengfelder, Eva, Scott, Fiona, Chou, Takaaki, Taniwaki, Masafumi, Yoshida, Isao, Ishizawa, Kenichi, Uike, Naokuni, Uoshima, Nobuhiko, Kamitsuji, Yuri, Iida, Shinsuke, Ohmine, Ken, Nosaka, Kisato, Ide, Kazuhiko, Ishikawa, Takayuki, Desjardins, Pierre, Finn, Nicholas, Zhu, Jun, Li, Wei, Yu, Li, Ren, Hanyun, Shi, Yuan Kai, Wu, Gang, Hong, Xiaonan, Zhang, Qingyuan, Feng, Jifeng, Zhan, Rong, Lin, Tongyu, Leppa, Sirpa, Costello, Regis, Tempescul, Adrian, Sanhes, Laurence, Tournilhac, Olivier, Kirchen, Heinz, Hebart, Holger, Weide, Rudolf, Jentsch-Ullrich, Kathleen, Avivi, Irit, Nagler, Arnon, Gurion, Ronit, Shpilberg, Ofer, Leoni, Pietro, Baldini, Luca, Samoylova, Olga, Myasnikov, Alexandr, Tan, Tran-Der, Chang, Hung, Kumagai, Kyoya, Tsukamoto, Norifumi, Tsukasaki, Kunihiro, Beatty, Patrick, Usui, Noriko, Izutsu, Koji, Murayama, Tohru, Ichinohe, Tatsuo, Kubo, Kohmei, Ishida, Fumihiro, Beck, J. Thaddeus, Griesinger, Frank, Osmanov, Dzhelil, Dakhil, Shaker, Clavert, Aline, Maruyama, Dai, Terui, Yasuhito, Yamamoto, Kazuhito, Eigendorff, Ekkehard, Kobayashi, Tsutomu, Ichikawa, Satoshi, Choi, Ilseung, Wada, Katsuya, Kikukawa, Yoshitaka, Matsuoka, Masao, Yoshino, Takayuki, Minami, Yosuke, Trotman, Judith, Barrington, Sally F, Belada, David, Meignan, Michel, MacEwan, Robert, Owen, Carolyn, Ptáčník, Václav, Rosta, András, Fingerle-Rowson, Günter R, Zhu, Jiawen, Nielsen, Tina, Sahin, Deniz, Hiddemann, Wolfgang, Marcus, Robert E, and Davies, Andrew

Published
2018
Full Text
View/download PDF

5. S222: EPCORITAMAB WITH RITUXIMAB + LENALIDOMIDE (R2) PROVIDES DURABLE RESPONSES IN PATIENTS WITH HIGH-RISK FOLLICULAR LYMPHOMA, REGARDLESS OF POD24 STATUS

Author

Sureda, Anna, primary, Falchi, Lorenzo, additional, Leppa, Sirpa, additional, Vermaat, Joost, additional, Holte, Harald, additional, Hutchings, Martin, additional, Lugtenburg, Pieternella, additional, de Vos, Sven, additional, Abrisqueta, Pau, additional, Nijland, Marcel, additional, Merryman, Reid W., additional, Christensen, Jacob Haaber, additional, Wahlin, Bjorn, additional, Linton, Kim, additional, Wang, Liwei, additional, Abbas, Aqeel, additional, Rana, Ali, additional, Quadri, Syed, additional, and Belada, David, additional

Published
2023
Full Text
View/download PDF

6. P1129: GLOFITAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL): EXTENDED FOLLOW-UP AND LANDMARK ANALYSES FROM A PIVOTAL PHASE II STUDY

Author

Hutchings, Martin, primary, Carlo-Stella, Carmelo, additional, Morschhauser, Franck, additional, Dickinson, Michael, additional, Bachy, Emmanuel, additional, Cartron, Guillaume, additional, Khan, Cyrus, additional, Tani, Monica, additional, Martinez-Lopez, Joaquín, additional, Bartlett, Nancy L., additional, Salar, Antonio, additional, Brody, Joshua, additional, Leppa, Sirpa, additional, Baumlin, Pauline, additional, Lundberg, Linda, additional, Relf, James, additional, Xie, Yuying, additional, Bottos, Alessia, additional, Humphrey, Kathryn, additional, and Falchi, Lorenzo, additional

Published
2023
Full Text
View/download PDF

7. Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma

Author

Reddy, Anupama, Zhang, Jenny, Davis, Nicholas S., Moffitt, Andrea B., Love, Cassandra L., Waldrop, Alexander, Leppa, Sirpa, Pasanen, Annika, Meriranta, Leo, Karjalainen-Lindsberg, Marja-Liisa, Nørgaard, Peter, Pedersen, Mette, Gang, Anne O., Høgdall, Estrid, Heavican, Tayla B., Lone, Waseem, Iqbal, Javeed, Qin, Qiu, Li, Guojie, Kim, So Young, Healy, Jane, Richards, Kristy L., Fedoriw, Yuri, Bernal-Mizrachi, Leon, Koff, Jean L., Staton, Ashley D., Flowers, Christopher R., Paltiel, Ora, Goldschmidt, Neta, Calaminici, Maria, Clear, Andrew, Gribben, John, Nguyen, Evelyn, Czader, Magdalena B., Ondrejka, Sarah L., Collie, Angela, Hsi, Eric D., Tse, Eric, Au-Yeung, Rex K.H., Kwong, Yok-Lam, Srivastava, Gopesh, Choi, William W.L., Evens, Andrew M., Pilichowska, Monika, Sengar, Manju, Reddy, Nishitha, Li, Shaoying, Chadburn, Amy, Gordon, Leo I., Jaffe, Elaine S., Levy, Shawn, Rempel, Rachel, Tzeng, Tiffany, Happ, Lanie E., Dave, Tushar, Rajagopalan, Deepthi, Datta, Jyotishka, Dunson, David B., and Dave, Sandeep S.

Published
2017
Full Text
View/download PDF

8. Mutations of ATM Confer a Risk of Inferior Survival in Patients with TP53-wild Type Mantle Cell Lymphoma

Author

Koff, Jean L., primary, Kositsky, Rachel, additional, Jaye, David L, additional, Churnetski, Michael C., additional, Baird, Katelin, additional, O'Leary, Colin B., additional, Flowers, Christopher R., additional, Leppa, Sirpa, additional, Karjalainen-Lindsberg, Marja-Liisa, additional, Li, Shaoying, additional, Xu, Jie, additional, Pedersen, Mette Ø, additional, Gang, Anne Ortved, additional, Naresh, Kikkeri N, additional, Leeman-Neill, Rebecca J, additional, Au Yeung, Kwok Him Rex, additional, Qureishi, Hina Naushad, additional, Iqbal, Javeed, additional, Chapman-Fredricks, Jennifer R, additional, McCall, Chad M., additional, Crump, Michael, additional, Chadburn, Amy, additional, Mulvey, Erin C., additional, Lossos, Izidore S., additional, Ondrejka, Sandra L., additional, Hsi, Eric D., additional, Louissaint, Abner, additional, Martin, Haley, additional, Tse, Eric, additional, Love, Cassandra, additional, Dave, Tushar, additional, Parker, Clay, additional, Ong, Choon Kiat, additional, Evans, Andrew G, additional, Behdad, Amir, additional, Yang, Lixin, additional, Reddy, Nishitha, additional, Arildsen, Mary Ann, additional, Juskevicius, Ridas, additional, Yan, Jiong, additional, Czader, Magdalena, additional, Evens, Andrew M., additional, Soliman, Dina Sameh, additional, Fedoriw, Yuri, additional, Dave, Sandeep S., additional, and Cohen, Jonathon B., additional

Published
2022
Full Text
View/download PDF

10. Biomarker-Driven Treatment Strategy in High-Risk Large B-Cell Lymphoma: Final Results of a Nordic Phase 2 Study

Author

Leppa, Sirpa, primary, Jørgensen, Judit M., additional, Karjalainen-Lindsberg, Marja-Liisa, additional, Beiske, Klaus, additional, Pedersen, Mette, additional, Drott, Kristina, additional, Pasanen, Annika, additional, Karihtala, Kristiina, additional, Mannisto, Susanna, additional, Meriranta, Leo, additional, Wold, Bente, additional, Brodtkorb, Marianne, additional, Fagerli, Unn Merete, additional, Larsen, Thomas S., additional, Munksgaard, Lars, additional, Sunela, Kaisa, additional, Fluge, Øystein, additional, Jyrkkio, Sirkku, additional, Brown, Peter de Nully, additional, and Holte, Harald, additional

Published
2022
Full Text
View/download PDF

12. Serum Proteome Profiling Reveals Inflammatory, Molecular and Prognostic Information Beyond the Ctdna in Aggressive B-Cell Lymphomas

Author

Arffman, Maare, primary, Meriranta, Leo, additional, Holte, Harald, additional, Jørgensen, Judit, additional, Brown, Peter De Nully, additional, Jyrkkio, Sirkku, additional, Jerkeman, Mats, additional, Fluge, Øystein, additional, Björkholm, Magnus, additional, Autio, Matias, additional, Leivonen, Suvi-Katri, additional, and Leppa, Sirpa, additional

Published
2022
Full Text
View/download PDF

13. Efficacy and Safety of Ibrutinib Combined with Standard First-Line Treatment or As Substitute for Autologous Stem Cell Transplantation in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network

Author

Dreyling, Martin, primary, Doorduijn, Jeanette K., additional, Gine, Eva, additional, Jerkeman, Mats, additional, Walewski, Jan, additional, Hutchings, Martin, additional, Mey, Ulrich, additional, Riise, Jon, additional, Trneny, Marek, additional, Vergote, Vibeke K.J., additional, Celli, Melania, additional, Shpilberg, Ofer, additional, Gomes da Silva, Maria, additional, Leppa, Sirpa, additional, Jiang, Linmiao, additional, Pott, Christiane, additional, Klapper, Wolfram, additional, Gözel, Döndü, additional, Schmidt, Christian, additional, Unterhalt, Michael, additional, Ladetto, Marco, additional, and Hoster, Eva, additional

Published
2022
Full Text
View/download PDF

14. Nodular Lymphocyte Predominant Hodgkin Lymphoma with Splenic Involvement Is Characterized By Inflamed Tumor Microenvironment, High Expression of Checkpoint Molecule Gene-Signature and Adverse Outcome

Author

Kalashnikov, Ilja, primary, Karjalainen-Lindsberg, Marja-Liisa, additional, Kovanen, Panu, additional, Dunkel, Johannes, additional, Pasanen, Annika, additional, Kositsky, Rachel, additional, Ondrejka, Sarah L., additional, Hsi, Eric D., additional, Evans, Andrew G, additional, Pedersen, Mette Ø, additional, Norgaard, Peter H., additional, Gang, Anne Ortved, additional, Czader, Magdalena, additional, Zhou, Jiehao, additional, Xu, Mina L, additional, Paulson, Nathan, additional, Juskevicius, Ridas, additional, Natkunam, Yasodha, additional, Louissaint, Abner, additional, Martin, Haley, additional, Thacker, Elizabeth, additional, Love, Cassandra, additional, Tian, Shari, additional, Ong, Choon Kiat, additional, Cheng, Chee Leong, additional, McCall, Chad M., additional, Koff, Jean L., additional, Younes, Sheren F., additional, Arildsen, Mary Ann, additional, Chapman-Fredricks, Jennifer R, additional, Amador, Catalina, additional, Fedoriw, Yuri, additional, Casulo, Carla, additional, Chadburn, Amy, additional, Sojitra, Payal, additional, Behdad, Amir, additional, Tse, Eric, additional, Naresh, Kikkeri N, additional, Yin, C. Cameron, additional, Goswami, Rashmi S., additional, Dave, Sandeep, additional, and Leppa, Sirpa, additional

Published
2022
Full Text
View/download PDF

16. Characterization and Clinical Impact of the Tumor Microenvironment of Post-Transplant Large B-Cell Lymphoma

Author

Leivonen, Suvi-Katri, primary, Friman, Terhi, additional, Vaittinen, Samuli, additional, Wind Jensen, Andreas, additional, d'Amore, Francesco Annibale, additional, Hamilton-Dutoit, Stephen Jacques, additional, Holte, Harald, additional, Beiske, Klaus, additional, Kovanen, Panu, additional, Räty, Riikka, additional, and Leppa, Sirpa, additional

Published
2022
Full Text
View/download PDF

19. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial

Author

Salles, Gilles, Seymour, John Francis, Offner, Fritz, López-Guillermo, Armando, Belada, David, Xerri, Luc, Feugier, Pierre, Bouabdallah, Réda, Catalano, John Vincent, Brice, Pauline, Caballero, Dolores, Haioun, Corinne, Pedersen, Lars Moller, Delmer, Alain, Simpson, David, Leppa, Sirpa, Soubeyran, Pierre, Hagenbeek, Anton, Casasnovas, Olivier, Intragumtornchai, Tanin, Fermé, Christophe, da Silva, Maria Gomes, Sebban, Catherine, Lister, Andrew, Estell, Jane A, Milone, Gustavo, Sonet, Anne, Mendila, Myriam, Coiffier, Bertrand, and Tilly, Hervé

Published
2011
Full Text
View/download PDF

20. Protein Profiling Identify Distinct Tumor-Tissue Protein Expression Pattern Specific for Relapsing Diffuse Large B-Cell Lymphoma

Author

Ludvigsen, Maja, primary, Wilken, Diani, additional, Karjalainen-Lindsberg, Marja-Liisa, additional, Beiske, Klaus, additional, Pedersen, Lars, additional, Delabie, Jan, additional, d'Amore, Francesco, additional, Holte, Harald, additional, Leppa, Sirpa, additional, Jørgensen, Judit, additional, and Honoré, Bent, additional

Published
2021
Full Text
View/download PDF

21. ALK-Negative Anaplastic Large Cell Lymphomas Encompass Distinct Subgroups Including an ALK-Positive-like Subgroup with Favorable Prognosis

Author

Au Yeung, Kwok Him Rex, primary, Russell, Veronica, additional, Choi, William, additional, Wong, Alice, additional, Tsui, Lawrence, additional, Lee, Yu Yan Carmen, additional, Li, Jamilla, additional, Gill, Harinder, additional, Ip, Ho-Wan, additional, Kwong, Yok Lam, additional, Dave, Tushar, additional, Ondrejka, Sarah L., additional, Bhagat, Govind, additional, Chadburn, Amy, additional, Rutherford, Sarah C., additional, Koff, Jean L., additional, Jaye, David L, additional, Czader, Magdalena, additional, Louissaint, Abner, additional, Li, Shaoying, additional, Xu, Jie, additional, Yin, C. Cameron, additional, Ong, Choon Kiat, additional, Cheng, Chee Leong, additional, Behdad, Amir, additional, Evens, Andrew M., additional, Norgaard, Peter H., additional, Gang, Anne Ortved, additional, Leppa, Sirpa, additional, Karjalainen-Lindsberg, Marja-Liisa, additional, Chapman, Jennifer R, additional, Amador, Catalina, additional, Iqbal, Javeed, additional, Fedoriw, Yuri, additional, Bogusz, Agata M., additional, Evans, Andrew G, additional, Juskevicius, Ridas, additional, Hsi, Eric D., additional, Naresh, Kikkeri N, additional, Dave, Sandeep S., additional, and Tse, Eric, additional

Published
2021
Full Text
View/download PDF

22. The Atlas of Blood Cancer Genomes (ABCG) Project: A Comprehensive Molecular Characterization of Leukemias and Lymphomas

Author

Love, Cassandra, primary, Pillai, Raju, additional, Ondrejka, Sarah L., additional, Bhagat, Govind, additional, Chadburn, Amy, additional, McKinney, Matthew, additional, Koff, Jean L., additional, Soliman, Dina Sameh, additional, Czader, Magdalena, additional, Louissaint, Abner, additional, Li, Shaoying, additional, Ong, Choon Kiat, additional, Behdad, Amir, additional, Evens, Andrew M., additional, Natkunam, Yasodha, additional, Norgaard, Peter H., additional, Leppa, Sirpa, additional, Tse, Eric, additional, Chapman, Jennifer R, additional, Amador, Catalina, additional, Fedoriw, Yuri, additional, Bogusz, Agata M., additional, Evans, Andrew G, additional, Goswami, Rashmi S., additional, Juskevicius, Ridas, additional, Xu, Mina L., additional, Naresh, Kikkeri N, additional, Xiong, Barbara, additional, Snowden, Adam, additional, Thurman, Anabel, additional, Smith, Eileen, additional, Dave, Tushar, additional, Kositsky, Rachel, additional, Thakkar, Devang, additional, Russell, Veronica, additional, Roth, Caroline J, additional, and Dave, Sandeep, additional

Published
2021
Full Text
View/download PDF

25. Epcoritamab SC Monotherapy Leads to Deep and Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma: First Data Disclosure from the Epcore NHL-1 Follicular Lymphoma Dose-Expansion Cohort

Author

Linton, Kim, Jurczak, Wojciech, Lugtenburg, Pieternella, Gyan, Emmanuel, Sureda Balari, Anna Maria, Christensen, Jacob Haaber, Hess, Brian, Tilly, Hervé, Cordoba, Raul, Lewis, David, Okada, Craig, Hutchings, Martin, Clausen, Michael Roost, Vitolo, Umberto, Cochrane, Tara, Leppa, Sirpa, Chamuleau, Martine E.D., Conlon, Rebekah, Favaro, Elena, Gernhardt, Diana, Altintas, Isil, Liu, Yan, and Thieblemont, Catherine

Published
2023
Full Text
View/download PDF

26. Prognostic impact of soluble CD163 in patients with diffuse large B-cell lymphoma

Author

Vajavaara, Heli, Ekeblad, Frida, Holte, Harald, Jorgensen, Judit, Leivonen, Suvi-Katri, Berglund, Mattias, Kamper, Peter, Moller, Holger J., d'Amore, Francesco, Molin, Daniel, Enblad, Gunilla, Ludvigsen, Maja, Glimelius, Ingrid, Leppa, Sirpa, Vajavaara, Heli, Ekeblad, Frida, Holte, Harald, Jorgensen, Judit, Leivonen, Suvi-Katri, Berglund, Mattias, Kamper, Peter, Moller, Holger J., d'Amore, Francesco, Molin, Daniel, Enblad, Gunilla, Ludvigsen, Maja, Glimelius, Ingrid, and Leppa, Sirpa

Published
2021
Full Text
View/download PDF

27. Prognostic impact of soluble CD163 in patients with diffuse large B-cell lymphoma

Author

Vajavaara, Heli, primary, Ekeblad, Frida, additional, Holte, Harald, additional, Jorgensen, Judit, additional, Leivonen, Suvi-Katri, additional, Berglund, Mattias, additional, Kamper, Peter, additional, Moller, Holger J., additional, D’Amore, Francesco, additional, Molin, Daniel, additional, Enblad, Gunilla, additional, Ludvigsen, Maja, additional, Glimelius, Ingrid, additional, and Leppa, Sirpa, additional

Published
2021
Full Text
View/download PDF

28. Mutations of ATMConfer a Risk of Inferior Survival in Patients with TP53-wild Type Mantle Cell Lymphoma

Author

Koff, Jean L., Kositsky, Rachel, Jaye, David L, Churnetski, Michael C., Baird, Katelin, O'Leary, Colin B., Flowers, Christopher R., Leppa, Sirpa, Karjalainen-Lindsberg, Marja-Liisa, Li, Shaoying, Xu, Jie, Pedersen, Mette Ø, Gang, Anne Ortved, Naresh, Kikkeri N, Leeman-Neill, Rebecca J, Au Yeung, Kwok Him Rex, Qureishi, Hina Naushad, Iqbal, Javeed, Chapman-Fredricks, Jennifer R, McCall, Chad M., Crump, Michael, Chadburn, Amy, Mulvey, Erin C., Lossos, Izidore S., Ondrejka, Sandra L., Hsi, Eric D., Louissaint, Abner, Martin, Haley, Tse, Eric, Love, Cassandra, Dave, Tushar, Parker, Clay, Ong, Choon Kiat, Evans, Andrew G, Behdad, Amir, Yang, Lixin, Reddy, Nishitha, Arildsen, Mary Ann, Juskevicius, Ridas, Yan, Jiong, Czader, Magdalena, Evens, Andrew M., Soliman, Dina Sameh, Fedoriw, Yuri, Dave, Sandeep S., and Cohen, Jonathon B.

Published
2022
Full Text
View/download PDF

31. STAT3 Mutation Is Associated with STAT3 Activation in CD30(+) ALK(-) ALCL

Author

Andersson, Emma I., Bruck, Oscar, Braun, Till, Mannisto, Susanna, Saikko, Leena, Lagstrom, Sonja, Ellonen, Pekka, Leppa, Sirpa, Herling, Marco, Kovanen, Panu E., Mustjoki, Satu, Andersson, Emma I., Bruck, Oscar, Braun, Till, Mannisto, Susanna, Saikko, Leena, Lagstrom, Sonja, Ellonen, Pekka, Leppa, Sirpa, Herling, Marco, Kovanen, Panu E., and Mustjoki, Satu

Abstract

Peripheral T-cell lymphomas (PTCL) are a heterogeneous, and often aggressive group of non-Hodgkin lymphomas. Recent advances in the molecular and genetic characterization of PTCLs have helped to delineate differences and similarities between the various subtypes, and the JAK/STAT pathway has been found to play an important oncogenic role. Here, we aimed to characterize the JAK/STAT pathway in PTCL subtypes and investigate whether the activation of the pathway correlates with the frequency of STAT gene mutations. Patient samples from AITL (n = 30), ALCL (n = 21) and PTCL-NOS (n = 12) cases were sequenced for STAT3, STAT5B, JAK1, JAK3, and RHOA mutations using amplicon sequencing and stained immunohistochemically for pSTAT3, pMAPK, and pAKT. We discovered STAT3 mutations in 13% of AITL, 13% of ALK(+) ALCL, 38% of ALK ALCL and 17% of PTCL-NOS cases. However, no STAT5B mutations were found and JAK mutations were only present in ALK(-) ALCL (15%). Concurrent mutations were found in all subgroups except ALK(+) ALCL where STAT3 mutations were always seen alone. High pY-STAT3 expression was observed especially in AITL and ALCL samples. When studying JAK-STAT pathway mutations, pY-STAT3 expression was highest in PTCLs harboring either JAK1 or STAT3 mutations and CD30(+) phenotype representing primarily ALK ALCLs. Further investigation is needed to elucidate the molecular mechanisms of JAK-STAT pathway activation in PTCL.

Published
2020

33. Genomic Profiling of Circulating Tumor DNA Reveals Patterns of Response and Refractoriness in Aggressive B-Cell Lymphoma - a Nordic Lymphoma Group Correlative Study

Author

Meriranta, Leo, primary, Alkodsi, Amjad, additional, Pasanen, Annika, additional, Lepistö, Maija, additional, Blaker, Yngvild Nuvin, additional, Autio, Matias, additional, Jørgensen, Judit, additional, Jerkeman, Mats, additional, Holte, Harald, additional, Ellonen, Pekka, additional, and Leppa, Sirpa, additional

Published
2019
Full Text
View/download PDF

34. The DLBCL90 Double-Hit Gene Expression Signature Is Not Associated with Inferior Survival in Young High-Risk Patients with Diffuse Large B-Cell Lymphoma Treated with Dose-Intensive Immunochemotherapy

Author

Isaksen, Kathrine T., primary, Beiske, Klaus, additional, Smeland, Erlend B., additional, Jørgensen, Judit, additional, Brodtkorb, Marianne, additional, Myklebust, June Helen, additional, Jerkeman, Mats, additional, Meriranta, Leo, additional, Karjalainen-Lindsberg, Marja-Liisa, additional, Leppa, Sirpa, additional, Scott, David W., additional, Holte, Harald, additional, and Blaker, Yngvild Nuvin, additional

Published
2019
Full Text
View/download PDF

36. Mutational Dynamics and Evolutionary Divergence in DLBCL: A Call for Relapse Sampling

Author

Wise, Jillian F., primary, Nakken, Sigve, additional, Steen, Chloé B, additional, Vodák, Daniel, additional, Trøen, Gunhild, additional, Johannessen, Bjarne, additional, Lingjærde, Ole Christian, additional, Hilden, Vera, additional, Blaker, Yngvild Nuvin, additional, Bai, Baoyan, additional, Aasheim, Lars B., additional, Pasanen, Annika, additional, Lorenz, Suzanne, additional, Sveen, Anita, additional, Lothe, Ragnhild, additional, Myklebost, Ola, additional, Leppa, Sirpa, additional, Meza-Zepeda, Leonardo, additional, Beiske, Klaus, additional, Lawrence, Michael S., additional, Hovig, Eivind, additional, Myklebust, June Helen, additional, Smeland, Erlend B., additional, and Holte, Harald, additional

Published
2019
Full Text
View/download PDF

39. Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study

Author

Bachy, Emmanuel, primary, Seymour, John F., additional, Feugier, Pierre, additional, Offner, Fritz, additional, López-Guillermo, Armando, additional, Belada, David, additional, Xerri, Luc, additional, Catalano, John V., additional, Brice, Pauline, additional, Lemonnier, François, additional, Martin, Alejandro, additional, Casasnovas, Olivier, additional, Pedersen, Lars M., additional, Dorvaux, Véronique, additional, Simpson, David, additional, Leppa, Sirpa, additional, Gabarre, Jean, additional, da Silva, Maria G., additional, Glaisner, Sylvie, additional, Ysebaert, Loic, additional, Vekhoff, Anne, additional, Intragumtornchai, Tanin, additional, Le Gouill, Steven, additional, Lister, Andrew, additional, Estell, Jane A., additional, Milone, Gustavo, additional, Sonet, Anne, additional, Farhi, Jonathan, additional, Zeuner, Harald, additional, Tilly, Hervé, additional, and Salles, Gilles, additional

Published
2019
Full Text
View/download PDF

41. Long-Term Efficacy and Safety from the Copanlisib CHRONOS-1 Study in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma

Author

Dreyling, Martin Santoro, Armando Mollica, Luigina Leppa, Sirpa Follows, George A. Lenz, Georg Kim, Won Seog and Nagler, Arnon Panayiotidis, Panayiotis Demeter, Judit Ozcan, Muhit Kosinova, Marina Bouabdallah, Krimo Morschhauser, Franck Stevens, Don Trevarthen, David Rodrigues, Liana and Hiemeyer, Florian Wang, MingLu Garcia-Vargas, Jose Childs, Barrett H. Zinzani, Pier Luigi

Published
2018

42. Immunogenomic Landscape of Hematological Malignancies

Author

Dufva, Olli, primary, Pölönen, Petri, additional, Brück, Oscar, additional, Keränen, Mikko A, additional, Mehtonen, Juha, additional, Siitonen, Sanna M., additional, Leivonen, Suvi-Katri, additional, Meriranta, Leo, additional, Leppa, Sirpa, additional, Nykter, Matti, additional, Lohi, Olli, additional, Heinäniemi, Merja, additional, and Mustjoki, Satu, additional

Published
2018
Full Text
View/download PDF

43. B-CAP (brentuximab vedotin, cyclophosphamide, doxorubicin and predniso(lo)Ne) in Older Patients with Advanced-Stage Hodgkin Lymphoma: Results of a Phase II Intergroup Trial By the German Hodgkin Study Group (GHSG) and the Nordic Lymphoma Group (NLG)

Author

Boell, Boris, primary, Fosså, Alexander, additional, Goergen, Helen, additional, Kamper, Peter, additional, Leppa, Sirpa, additional, Molin, Daniel, additional, Meissner, Julia, additional, Ritter, Ellen, additional, Christensen, Jacob H., additional, Hutchings, Martin, additional, Fuchs, Michael, additional, Engert, Andreas, additional, Kobe, Carsten, additional, and Borchmann, Peter, additional

Published
2018
Full Text
View/download PDF

44. Outcomes for Patients with High-Risk Relapsed or Refractory Indolent B-Cell Lymphoma Treated with Copanlisib in the CHRONOS-1 Study

Author

Santoro, Armando, primary, Mollica, Luigina, additional, Leppa, Sirpa, additional, Follows, George A, additional, Lenz, Georg, additional, Kim, Won Seog, additional, Nagler, Arnon, additional, Dimou, Maria, additional, Demeter, Judit, additional, Magagnoli, Massimo, additional, Rodrigues, Liana, additional, Wirtz, Oliver, additional, Hiemeyer, Florian, additional, Liu, Li, additional, Koechert, Karl, additional, Garcia-Vargas, Jose, additional, Childs, Barrett H, additional, Zinzani, Pier Luigi, additional, and Dreyling, Martin H., additional

Published
2018
Full Text
View/download PDF

45. Young High Risk Patients with MYC/BCL2 Double Hit Lymphoma, BCL2+ and/or Germinal Centre B-Cell like Diffuse Large B-Cell Lymphoma Benefit from Dose-Dense Chemoimmunotherapy Including Early CNS Prophylaxis: Analysis of Data from the Nordic Lymphoma Group CRY-04 and Chic Trials

Author

Leppa, Sirpa, primary, Jørgensen, Judit, additional, Meriranta, Leo, additional, Beiske, Klaus, additional, Delabie, Jan M.A., additional, Ralfkiaer, Elisabeth, additional, Spetalen, Signe, additional, Karjalainen-Lindsberg, Marja-Liisa, additional, and Holte, Harald, additional

Published
2018
Full Text
View/download PDF

47. Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial

Author

Trotman, Judith, primary, Barrington, Sally F, additional, Belada, David, additional, Meignan, Michel, additional, MacEwan, Robert, additional, Owen, Carolyn, additional, Ptáčník, Václav, additional, Rosta, András, additional, Fingerle-Rowson, Günter R, additional, Zhu, Jiawen, additional, Nielsen, Tina, additional, Sahin, Deniz, additional, Hiddemann, Wolfgang, additional, Marcus, Robert E, additional, Davies, Andrew, additional, Hertzberg, Mark, additional, Grigg, Andrew, additional, Cannell, Paul, additional, Quach, Hang, additional, Opat, Stephen, additional, Tam, Constantine, additional, Marlton, Paula, additional, Janssens, Ann, additional, Offner, Fritz, additional, Van eygen, Koen, additional, Sangha, Randeep, additional, Mckay, Pam, additional, Wilson, Jonathan, additional, Van Der Jagt, Richard, additional, Roitman, Daryl, additional, Trneny, Marek, additional, Mayer, Jiri, additional, Le Du, Katell, additional, Solal-Celigny, Philippe, additional, Cartron, Guillaume, additional, Foussard, Charles, additional, Frickhofen, Norbert, additional, Schmidt, Peter, additional, Graeven, Ullrich, additional, Gaska, Tobias, additional, Schlag, Rudolf, additional, Sökler, Martin, additional, Prange-Krex, Gabriele, additional, Florschütz, Axel, additional, Lindemann, Hans-Walter, additional, Schimmelpfennig, Christoph, additional, Tonndorf, Solveig, additional, Hänel, Mathias, additional, Hess, Georg, additional, Schalk, Enrico, additional, Hütten, Heiko, additional, Doelken, Gottfried, additional, Pfreundschuh, Michael, additional, Keller, Ulrich, additional, Herold, Michael, additional, Forstpointner, Roswitha, additional, Vehling-Kaiser, Ursula, additional, Hoffmann, Martin, additional, Borbenyi, Zita, additional, Udvardy, Miklos, additional, Demeter, Judit, additional, Rambaldi, Alessandro, additional, Morra, Enrica, additional, Massimo, Federico, additional, Majolino, Ignazio, additional, Balzarotti, Monica, additional, Semenzato, Gianpietro, additional, Canales Albendea, Miguel Angel, additional, Peñalver Parraga, Francisco Javier, additional, Soler Campos, Alfonso, additional, Sancho Cia, Juan Manuel, additional, Marquez Navarro, Jose Antonio, additional, Grande Garcia, Carlos, additional, Nilsson-Ehle, Herman, additional, Mccarthy, Helen, additional, Pocock, Chris, additional, Sadullah, Shalal, additional, Malladi, Ram, additional, Radford, John, additional, Kanfer, Ed, additional, Kruger, Anton, additional, Culligan, Dominic, additional, Dyer, Martin, additional, Pettengell, Ruth, additional, Seymour, John, additional, Gribben, John, additional, Al-Ismail, Saad, additional, Al-Refaie, Faris, additional, Blesing, Norbert, additional, Macnamara, Christopher, additional, O'callaghan, Ann, additional, Haynes, Andrew, additional, Follows, George, additional, Johnson, Roderick, additional, Cunningham, David, additional, Bowles, Kristian, additional, Collins, Graham, additional, Gallop-Evans, Eve, additional, Robinson, Stephen, additional, Subash, Chezhian, additional, Bailey, James, additional, Holden, Viran, additional, Neidhart, Jeffrey, additional, De Oliveira, Moacyr, additional, Tezcan, Haluk, additional, Kim, Kevin, additional, Kambhampati, Suman, additional, Lanier, Keith, additional, Mcclean, John, additional, Tobinai, Kensei, additional, Hatake, Kiyohiko, additional, Ogura, Michinori, additional, Uchida, Toshiki, additional, Ando, Kiyoshi, additional, Kinoshita, Tomohiro, additional, Höhler, Thomas, additional, Stauder, Heribert, additional, Kirsch, Andreas, additional, Koenigsmann, Michael, additional, Kremers, Stephan, additional, Illmer, Thomas, additional, Witzens-Harig, Mathias, additional, La Roseé, Paul, additional, Dürig, Jan, additional, Kneba, Michael, additional, Hensel, Manfred, additional, Fuxius, Stefan, additional, Bergmann, Lothar, additional, Hübel, Kai, additional, Buske, Christian, additional, Marks, Reinhard, additional, Wulf, Gerald, additional, Lerchenmueller, Christian, additional, Schmits, Rudolf, additional, Reinwald, Mark, additional, Lengfelder, Eva, additional, Scott, Fiona, additional, Chou, Takaaki, additional, Taniwaki, Masafumi, additional, Yoshida, Isao, additional, Ishizawa, Kenichi, additional, Uike, Naokuni, additional, Uoshima, Nobuhiko, additional, Kamitsuji, Yuri, additional, Iida, Shinsuke, additional, Ohmine, Ken, additional, Nosaka, Kisato, additional, Ide, Kazuhiko, additional, Ishikawa, Takayuki, additional, Desjardins, Pierre, additional, Finn, Nicholas, additional, Zhu, Jun, additional, Li, Wei, additional, Yu, Li, additional, Ren, Hanyun, additional, Shi, Yuan Kai, additional, Wu, Gang, additional, Hong, Xiaonan, additional, Zhang, Qingyuan, additional, Feng, Jifeng, additional, Zhan, Rong, additional, Lin, Tongyu, additional, Leppa, Sirpa, additional, Costello, Regis, additional, Tempescul, Adrian, additional, Sanhes, Laurence, additional, Tournilhac, Olivier, additional, Kirchen, Heinz, additional, Hebart, Holger, additional, Weide, Rudolf, additional, Jentsch-Ullrich, Kathleen, additional, Avivi, Irit, additional, Nagler, Arnon, additional, Gurion, Ronit, additional, Shpilberg, Ofer, additional, Leoni, Pietro, additional, Baldini, Luca, additional, Samoylova, Olga, additional, Myasnikov, Alexandr, additional, Tan, Tran-Der, additional, Chang, Hung, additional, Kumagai, Kyoya, additional, Tsukamoto, Norifumi, additional, Tsukasaki, Kunihiro, additional, Beatty, Patrick, additional, Usui, Noriko, additional, Izutsu, Koji, additional, Murayama, Tohru, additional, Ichinohe, Tatsuo, additional, Kubo, Kohmei, additional, Ishida, Fumihiro, additional, Beck, J. Thaddeus, additional, Griesinger, Frank, additional, Osmanov, Dzhelil, additional, Dakhil, Shaker, additional, Clavert, Aline, additional, Maruyama, Dai, additional, Terui, Yasuhito, additional, Yamamoto, Kazuhito, additional, Eigendorff, Ekkehard, additional, Kobayashi, Tsutomu, additional, Ichikawa, Satoshi, additional, Choi, Ilseung, additional, Wada, Katsuya, additional, Kikukawa, Yoshitaka, additional, Matsuoka, Masao, additional, Yoshino, Takayuki, additional, and Minami, Yosuke, additional

Published
2018
Full Text
View/download PDF

48. Copanlisib treatment in patients with relapsed or refractory indolent B-cell lymphoma: Subgroup analyses of diabetic patients from the phase II CHRONOS-1 study.

Author

Dreyling, Martin H., primary, Leppa, Sirpa, additional, Comeau, Terrance, additional, Kosinova, Marina, additional, Lenz, Georg, additional, Nagler, Arnon, additional, Heo, Dae Seog, additional, Oh, Sung Yong, additional, Huang, Liping, additional, Wirtz, Oliver, additional, Miriyala, Ashok, additional, Garcia-Vargas, Jose E., additional, Childs, Barrett H., additional, and Zinzani, Pier Luigi, additional

Published
2018
Full Text
View/download PDF

49. B-CAP (brentuximab vedotin, cyclophosphamide, doxorubicin and predniso(lo)Ne) in Older Patients with Advanced-Stage Hodgkin Lymphoma: Results of a Phase II Intergroup Trial By the German Hodgkin Study Group (GHSG) and the Nordic Lymphoma Group (NLG)

Author

Boell, Boris, Fossa, Alexander, Goergen, Helen, Kamper, Peter, Leppa, Sirpa, Molin, Daniel, Meissner, Julia, Ritter, Ellen, Christensen, Jacob H., Hutchings, Martin, Fuchs, Michael, Engert, Andreas, Kobe, Carsten, Borchmann, Peter, Boell, Boris, Fossa, Alexander, Goergen, Helen, Kamper, Peter, Leppa, Sirpa, Molin, Daniel, Meissner, Julia, Ritter, Ellen, Christensen, Jacob H., Hutchings, Martin, Fuchs, Michael, Engert, Andreas, Kobe, Carsten, and Borchmann, Peter

Published
2018

50. Copanlisib in patients with relapsed or refractory follicular lymphoma.

Author

Dreyling, Martin H., primary, Santoro, Armando, additional, Leppa, Sirpa, additional, Demeter, Judit, additional, Follows, George, additional, Lenz, Georg, additional, Kim, Won Seog, additional, Mollica, Luigina, additional, Nagler, Arnon, additional, Diong, Colin Phipps, additional, Provencio, Mariano, additional, Stevens, Don A., additional, Trevarthen, David, additional, Magagnoli, Massimo, additional, Cupit, Lisa, additional, Yin, Shuxin, additional, Hiemeyer, Florian, additional, Garcia-Vargas, Jose E., additional, Childs, Barrett H., additional, and Zinzani, Pier Luigi, additional

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results